SEC Form 4 · accession 0001209191-16-122769
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
L Daniel Browne
Officer — CEO and President · Director
Period of report
May 19, 2016
Accepted (ET)
May 23, 2016 · 9:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 19, 2016 | F | 12,050 | $17.11 | D | 231,627 | D | |
| Common StockF2 | holding | — | — | — | 409 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents 12,050 shares disposed to satisfy tax withholding obligations that arose in connection with the vesting of 32,000 shares of restricted stock on May 19, 2016.
- F2These shares are held by the Dan and Brenda Browne Living Trust. Mr. Browne is a Trustee of the Dan and Brenda Browne Living Trust.